` RGBP (Regen BioPharma Inc) vs S&P 500 Comparison - Alpha Spread

RGBP
vs
S&P 500

Over the past 12 months, RGBP has underperformed S&P 500, delivering a return of -93% compared to the S&P 500's +12% growth.

Stocks Performance
RGBP vs S&P 500

Loading
RGBP
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
RGBP vs S&P 500

Loading
RGBP
S&P 500
Difference
www.alphaspread.com

Performance By Year
RGBP vs S&P 500

Loading
RGBP
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Regen BioPharma Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Regen BioPharma Inc
Glance View

Market Cap
731.7k USD
Industry
N/A

Regen Biopharma, Inc. is a biotechnology company, which focuses on the immunology and immunotherapy space. The company is headquartered in La Mesa, California and currently employs 1 full-time employees. The company went IPO on 2014-09-03. The firm is focused on immuno-oncology, stem cell/cancer stem cell, and gene silencing. The company is engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The firm focuses on the treatment of hematopoiesis (blood formation), breast cancer, liver cancer, leukemia, myelodysplastic syndrome, and aplastic anemia. The firm is also engaged in developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating molecular processes in cancer stem cell through its molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

RGBP Intrinsic Value
0.0074 USD
Undervaluation 4%
Intrinsic Value
Price
Back to Top